Filing Flows › Cytokinetics (CYTK) › R&D spending
Cytokinetics (CYTK) R&D spending by quarter
Cytokinetics' R&D spending was $99.3M in Q3 2026 (third quarter 2026), +2% from Q2 2026. Over the last 7 quarters it ranged from $95.5M (Q1 2026) to $110M (Q2 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $99.3M | +2% | +0.1% |
| Q2 2026 | $97.8M | +2% | -11% |
| Q1 2026 | $95.5M | -8% | -3% |
| Q4 2025 | $104M | +5% | — |
| Q3 2025 | $99.2M | -10% | — |
| Q2 2025 | $110M | +12% | — |
| Q1 2025 | $98.3M | — | — |
Q3 2026 at a glance
Cytokinetics, Q3 2026: revenue $47.6M (25× year over year), operating margin -351.3%, net loss $190M, operating cash flow −$124M. The chart follows the revenue to costs, profit and cash.
Questions
What is Cytokinetics' R&D spending?
Cytokinetics' R&D spending was $99.3M in Q3 2026 (third quarter 2026), +2% from Q2 2026.
How has Cytokinetics' R&D spending changed?
Over the last 7 quarters it ranged from $95.5M (Q1 2026) to $110M (Q2 2025).